Glancy Binkow & Goldberg LLP, Representing Shareholders of Caraco Pharmaceutical Laboratories, Ltd., Announces There Are 25 Days Remaining to Move for

Glancy Binkow & Goldberg LLP, Representing Shareholders of Caraco Pharmaceutical Laboratories, Ltd., Announces There Are 25 Days Remaining to Move for Appointment as Lead Plaintiff

Caraco is engaged primarily in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers. The Complaint charges Caraco and certain of the Company's executive officers with violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and S.E.C. Rule 10b-5, and further alleges that throughout the Class Period defendants failed to disclose, among other things, that the Company failed to meet the United States Food and Drug Administration’s (“FDA”) current Good Manufacturing Practice requirements and had failed to remedy repeat violations of FDA regulations previously observed and documented by the FDA, which significantly jeopardized the Company’s ability to gain FDA approval of pending new drug applications.

The Private Securities Litigation Reform Act of 1995 (“PSLRA”) requires the Court to appoint a “Lead Plaintiff” in this case. Any person or group who purchased Caraco securities during the Class Period and suffered a loss may ask the Court to be appointed as Lead Plaintiff, but must file a motion no later than the September 15, 2009 deadline.

Glancy Binkow & Goldberg LLP is a law firm with significant experience in prosecuting class actions, substantial expertise in actions involving corporate fraud, and is representing shareholders of Caraco in this litigation.